NAS:SPPI (USA) Also trade in: Germany

Spectrum Pharmaceuticals Inc

$ 8.18 -0.05 (-0.61%)
Volume: 909,306 Avg Vol (1m): 817,240
Market Cap $: 915.86 Mil Enterprise Value $: 609.98 Mil
P/E (TTM): 0.00 P/B: 3.28
Earnings Power Value -1.89
Net Current Asset Value 2.37
Tangible Book 2.49
Projected FCF -1.01
Median P/S Value 2.37
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked lower than
60.39% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
SPPI: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.2, Med: 6.64, Max: 17918
Current: 10000
0.2
17918
Equity-to-Asset 0.73
Equity-to-Asset ranked higher than
57.27% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
SPPI: 0.73
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.2, Med: 0.59, Max: 0.95
Current: 0.73
0.2
0.95
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.16
DISTRESS
GREY
SAFE
Beneish M-Score -4.05
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -173.17%
WACC 24.46%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -182.33
Operating Margin ranked higher than
54.29% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
SPPI: -182.33
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -182.33, Med: -34.57, Max: 30.17
Current: -182.33
-182.33
30.17
Net Margin % -156.46
Net Margin ranked higher than
56.06% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
SPPI: -156.46
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -156.46, Med: -43.76, Max: 35.19
Current: -156.46
-156.46
35.19
ROE % -40.82
ROE ranked higher than
57.53% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
SPPI: -40.82
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -51.49, Med: -24.2, Max: 39.19
Current: -40.82
-51.49
39.19
ROA % -29.87
ROA ranked higher than
63.56% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
SPPI: -29.87
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -29.87, Med: -12.49, Max: 23.98
Current: -29.87
-29.87
23.98
ROC (Joel Greenblatt) % -31911.40
ROC (Joel Greenblatt) ranked lower than
89.19% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
SPPI: -31911.4
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -31911.4, Med: -2078.83, Max: 3089.46
Current: -31911.4
-31911.4
3089.46
3-Year Total Revenue Growth Rate -12.40
3-Year Revenue Growth Rate ranked lower than
68.05% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
SPPI: -25
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -11.6, Max: 202.1
Current: -25
0
202.1
3-Year Total EBITDA Growth Rate -188.70
3-Year EBITDA Growth Rate ranked lower than
95.39% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
SPPI: -147
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -12.70
3-Year EPS w/o NRI Growth Rate ranked lower than
70.64% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
SPPI: -12.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -4.25, Max: 89.8
Current: -12.7
0
89.8

» SPPI's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SPPI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:VYGR NAS:CLVS NAS:CBAY HKSE:06826 NAS:RYTM NYSE:MYOV NAS:OMER NAS:FIXX NAS:DCPH NAS:WVE OSTO:RECI B NAS:IFRX NAS:VNDA NAS:MGNX NAS:KNSA NAS:ALDR NAS:NITE NAS:DRNA NAS:GTHX HKSE:01672
Traded in other countries NTR.Germany
Address 11500 South Eastern Avenue, Suite 240, Henderson, NV, USA, 89052
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. As an oncology products manufacturer, it develops drugs to combat various kinds of tumors. The SPI-2012 is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN addresses immediate intravesical instillation and post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Its other products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA.

Ratios

Current vs industry vs history
PB Ratio 3.28
PB Ratio ranked lower than
70.17% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
SPPI: 3.28
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.64, Med: 2.41, Max: 7.9
Current: 3.28
0.64
7.9
PS Ratio 11.09
PS Ratio ranked lower than
55.79% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
SPPI: 11.09
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.07, Med: 3.22, Max: 28.72
Current: 11.09
1.07
28.72
EV-to-EBIT -3.98
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
SPPI: -3.98
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -34.9, Med: -5.4, Max: 63.5
Current: -3.98
-34.9
63.5
EV-to-EBITDA -4.66
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
SPPI: -4.66
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -1739.5, Med: -5.1, Max: 128
Current: -4.66
-1739.5
128
EV-to-Revenue 7.74
EV-to-Revenue ranked lower than
53.83% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
SPPI: 7.74
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -1.1, Med: 2.7, Max: 28.4
Current: 7.74
-1.1
28.4
Current Ratio 4.84
Current Ratio ranked lower than
63.97% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
SPPI: 4.84
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.56, Med: 2.97, Max: 16.82
Current: 4.84
0.56
16.82
Quick Ratio 4.82
Quick Ratio ranked lower than
61.73% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
SPPI: 4.82
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.56, Med: 2.89, Max: 16.8
Current: 4.82
0.56
16.8
Days Inventory 68.27
Days Inventory ranked higher than
70.06% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
SPPI: 68.27
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 55.77, Med: 84.52, Max: 178.78
Current: 68.27
55.77
178.78
Days Sales Outstanding 69.15
Days Sales Outstanding ranked lower than
72.01% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
SPPI: 69.15
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 68.22, Med: 99.44, Max: 138.24
Current: 69.15
68.22
138.24
Days Payable 764.81
Days Payable ranked higher than
83.02% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
SPPI: 764.81
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 89.64, Med: 250.64, Max: 764.81
Current: 764.81
89.64
764.81

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -16.10
3-Year Share Buyback Rate ranked lower than
54.38% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
SPPI: -16.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -149.9, Med: -20.8, Max: -3.6
Current: -16.1
-149.9
-3.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.29
Price-to-Tangible-Book ranked lower than
80.20% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
SPPI: 3.29
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.66, Med: 6.86, Max: 581.43
Current: 3.29
0.66
581.43
Price-to-Median-PS-Value 3.45
Price-to-Median-PS-Value ranked lower than
93.81% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
SPPI: 3.45
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.18, Med: 2.84, Max: 4687.56
Current: 3.45
0.18
4687.56
Earnings Yield (Joel Greenblatt) % -25.17
Earnings Yield (Greenblatt) ranked higher than
59.20% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
SPPI: -25.17
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -1825.9, Med: -8, Max: 1754.4
Current: -25.17
-1825.9
1754.4

More Statistics

Revenue (TTM) (Mil) $ 78.84
EPS (TTM) $ -1.17
Beta 3.82
Volatility % 69.73
52-Week Range $ 6.22 - 25.29
Shares Outstanding (Mil) 111.96

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N